TLX Alert: Shareholders Losing Money Must Act Now!

Overview

Telix Pharmaceuticals Limited (Nasdaq/ASX: TLX) – a biopharmaceutical company specializing in cancer diagnostic and therapeutic radiopharmaceuticals – has seen its stock price collapse in 2025. After reaching an all-time high closing price of about $20.93 per share in February 2025, Telix’s American Depositary Shares (ADS) now trade near $9 (^[1]). This plunge represents roughly a 41% year-to-date decline (^[1]), erasing billions in market value and leaving many shareholders deep in the red. The steep drop coincided with significant negative developments, including an FDA rejection of a key product and a U.S. SEC investigation, which have spurred multiple shareholder lawsuits alleging the company misled investors (^[2]). In this report, we examine Telix’s fundamentals – dividend policy, leverage, coverage ratios, valuation, and the risks/red flags – to understand the challenges facing TLX shareholders and why urgent action or scrutiny is warranted.

Dividend Policy and Yield (AFFO/FFO)

No Dividend: Telix does not pay any dividend, as it has been reinvesting cash into growth and R&D. The company’s dividend yield is 0.00% and it has never made a payout to shareholders (^[3]). This is unsurprising for a clinical-stage biotech turned commercial pharma – all available capital is directed toward developing and commercializing its pipeline rather than returning cash to investors. AFFO/FFO Metrics: Traditional REIT metrics like Adjusted Funds From Operations (AFFO) or Funds From Operations (FFO) are not applicable for Telix, since it’s not a real estate or income-generating asset business. Instead, Telix’s financial performance is measured by revenue growth, profitability, and cash flow. Notably, 2023 was the company’s first year of positive earnings, with Telix achieving an inaugural net profit of A$5.2 million after years of losses (^[4]). This reflects the early stage of its profit cycle – Telix is still in growth mode, so investors cannot expect dividends in the foreseeable future.

Leverage and Debt Maturities

Capital Structure: Telix historically funded its operations through equity raises (and partnership revenues) during its development phase, carrying minimal debt. However, in mid-2024 the company took on significant leverage to fund expansion. Telix issued A$600 million (≈$398M USD) of convertible notes in July 2024 (^[5]). These notes bear a low interest rate of ~2.0–2.75% and are convertible to ordinary shares by 2029, effectively pushing out any principal repayment to that year (^[5]). The notes were listed on the Singapore Exchange and were considered attractive, low-cost financing that avoids dilution unless converted (^[5]). This long-dated debt means Telix faces no major debt maturity until 2029, giving it breathing room to execute its growth plan before any refinancing or repayment is due.

Debt Utilization: Proceeds from the convertible bond have been used to accelerate R&D and strategically strengthen Telix’s infrastructure. For example, Telix used ~US$230 million of the funds to acquire RLS (USA) Inc, the largest U.S. radiopharmacy network, in late 2024 (^[6]). This acquisition expanded Telix’s manufacturing and distribution footprint for radiopharmaceuticals, which is critical for ensuring reliable supply of its products. After funding this acquisition and other investments, Telix still held a substantial cash reserve. As of mid-2025 the company reported a cash balance of $207.2 million (USD) (^[7]), providing a liquidity cushion for ongoing trials and product launches. In summary, Telix’s leverage is moderate and largely composed of the single convertible bond due 2029. The distant maturity and cash on hand suggest no near-term solvency issues; however, the company now carries a net debt position for the first time, and investors must monitor how effectively this capital is deployed to generate returns before 2029.

Coverage and Fixed-Charge Obligations

Interest Coverage: With the new debt comes annual interest obligations, but Telix’s current earnings and cash flow appear capable of covering these costs as long as growth continues. The convertible notes pay a coupon of only a few percent, implying roughly A$12–17 million in annual interest expense. For context, Telix delivered adjusted EBITDA of A$99.3 million in 2024 (^[8]) and a pre-tax operating profit of A$82.1 million, which suggests healthy interest coverage on a cash basis (EBITDA/interest well above 5×). Indeed, even factoring in non-cash financing costs, Telix’s operations remain close to break-even: in the first half of 2025, the company had a small loss before tax of $4.8M USD – but this included $12.4M in non-cash interest expense from the convertible bonds and higher amortization from acquisitions (^[7]). Excluding those accounting charges, core operating profits were positive. Moreover, Telix generated +$17.7M in operating cash flow in H1 2025 (^[7]), indicating that cash earnings comfortably covered the cash interest outlay (the coupon) during that period.

Dividend or Fixed-Charge Coverage: Since Telix pays no dividend, dividend coverage isn’t a concern currently (retained cash is reinvested, not paid out). The key fixed charges to cover are interest on debt and growing R&D and SG&A expenses. On that front, Telix’s commercial success with its first product (Illuccix) has thus far funded its expansion. For example, product sales in 2024 were strong enough that Telix boosted R&D spend by ~50% while remaining profitable (^[4]) (^[4]). However, it’s worth noting that Telix’s newfound profitability is modest relative to its obligations. The interest expenses plus rising operating costs narrowly exceeded earnings in early 2025 (^[7]), showing that any significant hiccup in revenue growth could put pressure on coverage. With ~$200M in cash reserves (^[7]), Telix can absorb short-term shortfalls, but continued revenue and profit expansion are needed to maintain comfortable coverage of interest and future fixed charges (like potential debt repayment in 2029 if conversion doesn’t occur). In short, Telix’s fixed charges are being covered by current cash flows, but there is little margin for error if the growth story falters.

Valuation and Comparables

Revenue and Earnings Multiples: Telix’s valuation has been rich, reflecting high growth expectations. Even after the share price decline, the stock trades at a lofty multiple of current earnings and sales. At a share price around US$9 (A$14) in late 2025, Telix’s market capitalization is roughly US$3.1 billion (^[1]). For the 12 months ending Dec 2024, Telix’s revenue was about A$783 million (US$517M) (^[8]), meaning the stock is valued at approximately 6× trailing annual sales (^[1]). On a price-to-earnings basis, Telix looks even more expensive: using 2024’s net income (A$49.9M, ~US$33M) (^[8]) (^[8]), the trailing P/E is well above 100×. In fact, Yahoo Finance recently calculated Telix’s TTM P/E around 350+ (^[9]) (due to the very small EPS over the past year). This underscores that the market has been pricing in substantial future profit growth rather than valuing Telix on its current earnings alone.

Peer Comparison: By comparison, large established pharma companies typically trade at far lower multiples. For instance, blue-chip drug makers like AstraZeneca, Amgen, or Gilead trade around 15–20× earnings in today’s market (^[1]). Even high-growth biotechs with actual profits seldom sustain triple-digit P/E ratios. Telix’s elevated valuation was predicated on its strong revenue trajectory (sales more than tripled from 2022 to 2024 (^[4])) and the promise of pipeline expansion (i.e. new product approvals beyond its first product). This premium has started to deflate after recent setbacks – the stock’s 41% YTD drop (^[1]) implies a significant rerating. Nevertheless, Telix is still not “cheap” by conventional metrics: the company’s price is ~6× sales and over 100× last year’s earnings, which leaves little room for disappointment. Investors are effectively paying up for what Telix could earn in the future if its cancer therapies succeed. Should growth stall or pipeline programs fail, the downside could be severe given the high base valuation. Conversely, if Telix’s pipeline delivers on its potential (and revenue climbs into the billions as guided (^[8]) (^[8])), current prices might be justified or even undervalued. The divergence between Telix’s valuation and established pharma norms highlights the make-or-break nature of its pipeline – a key factor for shareholders to weigh.

Risks and Challenges

Telix faces a number of risks and headwinds that shareholders should carefully consider:

– Regulatory Setbacks: A core risk is the potential for delays or failures in obtaining regulatory approvals for new products. This was exemplified in August 2025, when the U.S. FDA issued a Complete Response Letter (CRL) rejecting Telix’s TLX250-CDx product (an imaging agent for kidney cancer) due to manufacturing and quality control deficiencies (^[10]). The FDA found that Telix’s scaled-up production process wasn’t sufficiently proven equivalent to what was used in clinical trials (^[10]). This setback not only delays the launch of a key new product, but also raises concerns about Telix’s manufacturing processes and oversight. The company believes it can address the FDA’s concerns “quickly” (^[10]), but there is no guarantee of how fast a resubmission and approval will occur. Every delay is time that competitors can capture market share (or new competing innovations can emerge), and it pushes out the timeline for Telix to diversify its revenue beyond its flagship product. Regulatory risk extends to Telix’s therapeutic pipeline as well – stringent FDA and international requirements mean any number of issues (efficacy shortfalls, safety signals, CMC issues, etc.) could derail a candidate after heavy investment. Telix must navigate these hurdles carefully to meet the high expectations baked into its valuation.

– Product Concentration and Competition: Currently, Telix’s financial performance is overwhelmingly driven by a single product – Illuccix®, its prostate cancer imaging agent. While Illuccix has enjoyed rapid adoption (driving over A$780M in sales in 2024 (^[8])), it operates in a competitive field. Lantheus Holdings’ Pylarify® (an F-18 labeled PSMA PET imaging agent) was first-to-market in the U.S. and is a direct competitor. According to Lantheus’s filings, Pylarify “currently competes with two commercially available Ga-68-based PSMA PET imaging agents from Telix and Novartis AG, and an F-18 PSMA agent from Blue Earth” (^[11]). In other words, Telix is not alone – bigger players like Novartis have their own PSMA imaging agents, and new diagnostics could emerge. If Illuccix loses market share or if pricing pressure increases (e.g. via competing tracers or healthcare cost pressures), Telix’s near-term revenues could plateau or decline. Furthermore, reimbursement and usage trends for prostate imaging will influence demand – any changes in clinical guidelines or insurer coverage could pose a risk. Competition is also intensifying on the therapeutic side: Telix’s pipeline (e.g. TLX592, an alpha-emitting therapy for prostate cancer (^[8])) eventually aims to compete with treatments like Novartis’s Pluvicto® (a radioligand therapy) and others in development. These large competitors have greater resources and established oncology franchises. Telix will need to demonstrate clear advantages in efficacy or safety to gain a foothold. Overall, Telix’s business is concentrated and competitive, so any stumble can have outsized impact on its financials.

– Pipeline Execution and R&D Risk: Telix is heavily investing in R&D to expand its product portfolio, which comes with inherent risk. In 2024 the company spent A$194.6 million on R&D – a 51% increase from the prior year (^[8]) – focusing on late-stage pipeline assets. Such aggressive spending is necessary to advance trials, but not all programs will succeed. Clinical and scientific risk is high in oncology: a promising therapy can fail in Phase III trials or face unforeseen safety issues. If Telix’s pipeline candidates (spanning prostate therapy, brain cancer, kidney cancer, etc.) do not ultimately gain approval, the heavy R&D expenditure will not translate into the hoped-for future revenues. The company’s theranostics strategy (pairing diagnostics and therapeutics) makes sense scientifically, but it requires coordination of multiple complex projects. There’s also execution risk in scaling the company from a single-product operation to a multi-product, global commercial enterprise. Telix’s recent acquisitions (e.g. manufacturing facilities, RLS network) bring integration challenges – management must successfully assimilate these and ensure they support the pipeline. Operational mishaps like the FDA CMC issues indicate room for improvement. Additionally, supply chain and production of radioisotopes is technically complex; Telix must secure reliable isotope supply (gallium-68, lutetium-177, etc.) and maintain strict quality controls to avoid future regulatory problems. Any disruption in production could jeopardize product availability and revenues, as well as the confidence of regulators.

– Financial and Leverage Risk: Although Telix is now profitable, its margins are still slim due to reinvestment, and it has taken on debt. The A$650M convertible bond due 2029 introduces a sizable obligation. While the interest rate is low, the eventual repayment or dilution risk is notable. If Telix’s stock price recovers above the conversion price by 2029, bondholders will convert to equity (diluting shareholders but sparing cash). However, if the stock underperforms or if investors lose confidence, Telix could face a scenario where it must redeem hundreds of millions in principal. For a company of Telix’s size, that could be challenging – it would likely require either a major refinancing or another capital raise at that time. Thus, Telix is implicitly betting on its future success to make this debt effectively self-vanishing via conversion. In the interim, high R&D and expansion costs could pressure free cash flow. We saw that Telix roughly broke even in the first half of 2025 when including bond interest and amortization (^[7]). Should any headwind cause a dip in Illuccix sales (or a costly delay in a new product launch), Telix might burn cash and potentially need additional financing. The company’s financial runway is strong for now (over $200M cash (^[7])), but not infinite. Investors should monitor Telix’s cash burn rate relative to its cash on hand, especially as it executes expensive late-stage trials.

– Legal and Reputational Risk: Recent events have introduced legal risk and potential damage to management’s credibility. In July 2025, Telix disclosed it received a U.S. SEC subpoena regarding its disclosures on prostate cancer therapy development (^[12]). This indicates the SEC is investigating whether Telix’s public statements misled investors or omitted material facts. Such investigations can lead to enforcement actions, restatements, or sanctions if wrongdoing is found (or at least create a cloud of uncertainty if they remain unresolved). Around the same time, Telix’s CEO and co-founder made large stock sales (see Red Flags below), and just a month later the FDA rejection hit – the sequence of events opens the company to speculation that insiders may have been aware of issues before the public, although no conclusions can be drawn yet. Regardless, the optics are poor, and Telix now faces the overhang of shareholder lawsuits. At least four law firms (e.g. Howard G. Smith, Glancy Prongay & Murray, Wolf Haldenstein, Levi & Korsinsky) have announced class-action lawsuits alleging Telix committed securities fraud by overstating its pipeline progress and supply chain robustness (^[2]) (^[13]). These lawsuits, while common after stock drops, will consume management’s attention and could result in financial settlements if proven. Perhaps more damaging is the reputational hit: investors may be less inclined to take Telix management at their word until this is cleared up. Overall, the legal and credibility issues pose a risk to Telix’s valuation – a company commanding a premium multiple must have investor trust. Any sustained erosion of that trust can compress the valuation (e.g. investors applying a larger discount to account for governance concerns).

Red Flags and Recent Developments

Several red flags have emerged in 2025 that current and prospective shareholders should note:

– SEC Subpoena & Stock Plunge (July 2025): On July 22, 2025, Telix shocked the market by revealing it had been subpoenaed by the U.S. SEC over its disclosures concerning prostate cancer therapeutics (^[2]). The next day, investors reacted with alarm: Telix’s stock “faceplanted” down as much as 16% intraday on the ASX (^[12]), hitting its lowest level in eight months. Management stated it was cooperating fully with the SEC inquiry (^[12]), but did not provide details, calling it a fact-finding mission. The lack of clarity and the implication that Telix’s prior statements may have been overly rosy or incomplete caused a swift loss of confidence. This is a red flag because SEC investigations in biotech often center on whether companies overhyped trial results or timelines. The probe suggests regulators saw potential inconsistencies in Telix’s communications about its prostate therapy pipeline (possibly TLX592 or related programs). Shareholders should be cautious until the scope and outcome of the SEC investigation are known – at best it could end with no action, but at worst it might validate claims of misleading statements.

– FDA Complete Response Letter (Aug 2025): As mentioned earlier, on Aug 28, 2025, Telix announced the FDA had rejected approval of its TLX250-CDx imaging agent, issuing a CRL citing Chemistry, Manufacturing, and Controls deficiencies (^[2]) (^[2]). This development is a glaring red flag for Telix’s operational execution. The FDA essentially found that Telix’s manufacturing scale-up for TLX250-CDx was not up to standard, which is concerning given the company’s heavy investment in manufacturing capabilities (one of the rationale behind the RLS acquisition was to ensure supply chain quality). The market’s response was punishing – Telix’s stock plunged 14% on the news to around A$15.80, making it the worst performer on the ASX200 that day (^[10]). Management’s claim that the issues can be addressed quickly is cold comfort until we see concrete progress. The CRL represents a material delay in Telix’s growth plans (pushing a potential new revenue stream further out) and raises a red flag about quality control and possibly oversight within Telix. Investors will recall that this is not a theoretical pipeline compound but a product that completed Phase 3 successfully – the fact that approval is held up by manufacturing comparability data suggests an avoidable lapse. Going forward, shareholders must watch if Telix overhauls its CMC processes or brings in additional expertise to prevent repeat issues for other pipeline products.

– Allegations of Misleading Statements: The combination of the SEC probe and the FDA setback has led to serious allegations that Telix misled investors during the first half of 2025. The class-action complaint claims Telix “materially overstated” the progress of its prostate cancer therapeutics and the quality of its supply chain/partners, rendering optimistic statements misleading (^[2]). In plain language, plaintiffs allege Telix painted an unjustifiably rosy picture of its pipeline and preparedness. These allegations are unproven at this stage, but the fact they are being taken up by multiple law firms is itself a red flag. If any evidence emerges that Telix’s management knew about manufacturing problems or development delays and failed to disclose them in a timely way, it would severely damage management’s credibility. Even absent a court verdict, the management team’s track record is under scrutiny. Investors should be wary of overly optimistic guidance or commentary – recent history suggests a gap between Telix’s public optimism and eventual outcomes (e.g. guiding for regulatory approvals that did not materialize on schedule).

– Insider Stock Sales at Peak Prices: Perhaps the most striking red flag is the timing of massive insider share sales. In late February 2025, as Telix’s stock was near record highs, two co-founders unloaded a huge stake in the company. Specifically, Telix’s CEO Dr. Christian Behrenbruch and co-founder Dr. Andreas Kluge each sold 2 million shares in an off-market block trade at A$29.50 per share (^[14]). The total proceeds were roughly A$118 million, representing a significant portion of their holdings. This sale was executed at only a ~5% discount to Telix’s all-time high (the stock had closed at $31.05 the prior day) (^[14]). The market’s reaction was immediate – Telix’s share price dropped ~9.4% intraday as news of the insider sell-down spread (^[14]). Management stated the sale was for personal diversification, but from a shareholder perspective the optics are very concerning: the CEO cashed out a large sum just weeks before the company hit turbulence. (Note that the sales occurred Feb 26–28, 2025; by July/August the SEC and FDA issues surfaced.) While this timing could be coincidental, it undeniably raises eyebrows. At best, it shows insiders thought the stock was fully valued at $29–30. At worst, one wonders if they anticipated potential setbacks. Large insider selling is a classic warning sign in equity markets, and here it happened at the peak of enthusiasm for Telix. Shareholders should keep an eye on any further insider transactions. The episode also feeds into the class-action narrative – plaintiffs will likely point to these sales as insiders “taking profit” while public investors later suffered losses. In summary, the insider sale at peak price is a glaring red flag that shouldn’t be ignored.

– Shareholder Legal Actions: By November 2025, multiple law firms have publicized calls for Telix shareholders to join class-action suits (^[13]). These include deadlines for investors who suffered losses to seek lead-plaintiff status. Such notices (from firms like Howard G. Smith, Glancy Prongay, Wolf Haldenstein, etc.) are fairly routine after a big drop, but the breadth of them underscores the perceived severity of Telix’s missteps. These legal actions could drag on for years. While Telix will likely have D&O insurance and legal defenses, the overhang of litigation is a red flag because it can constrain what management says publicly, potentially delay or complicate financing efforts, and result in settlement costs. Moreover, the court filings will bring unwanted attention – any discovery or revelations could air dirty laundry about Telix’s internal discussions around the time of the FDA and SEC issues. In short, the legal cloud adds another layer of risk for shareholders.

Taken together, these red flags paint a picture of a company that overstretched and stumbled in 2025. Rapid growth and market adulation turned into regulatory setbacks and credibility questions. Shareholders “must act now” in the sense of staying vigilant, demanding accountability, and if appropriate, exercising their rights (through legal action or governance channels) to protect their investment.

Open Questions for Shareholders

In light of the above, there are several open questions and uncertainties that Telix shareholders should be pressing for answers to:

– When and how will TLX250-CDx be approved? Telix says it can quickly address the FDA’s manufacturing concerns (^[10]), but no timeline has been given for resubmission of the BLA. Will the remediation require new trials or data, or can it be resolved with paperwork and inspections? Each quarter of delay costs potential revenue and prolongs Telix’s dependence on a single product. Investors need clarity on the path forward and timeline for TLX250-CDx (Zircon) approval in the U.S., and whether similar issues could affect approvals elsewhere (e.g. Europe).

– What is the status of Telix’s prostate therapy programs? The SEC’s subpoena suggests something may be amiss in Telix’s prostate cancer therapeutic pipeline disclosures (^[2]). Telix has touted assets like TLX592 (prostate radiotherapy) with encouraging early results (^[8]), but what is the realistic timeline for these entering Phase III or commercialization? Have there been delays or obstacles that were not fully communicated? Shareholders would benefit from a candid update on the progress, hurdles, and expected milestones for Telix’s therapeutic candidates in prostate cancer, given this is a focal point of both the company’s future and the allegations of overstatement.

– How will Telix ensure manufacturing and supply chain reliability? The FDA’s CMC-related rejection raises concern about Telix’s manufacturing scale-up processes. The company has acquired manufacturing assets (Cyclotron in Belgium, the RLS network in the U.S.) – but are these fully integrated and meeting quality standards? What corrective actions is Telix taking to bolster its CMC and quality assurance so that future filings (and the eventual TLX250 resubmission) won’t face similar issues? This question extends to supply chain: radiopharmaceutical production involves complex logistics (half-life limitations, etc.). Telix must persuade investors that it now has robust controls and contingency plans in place to deliver product at scale and at quality. Greater transparency on this front would help restore confidence.

– What will be the outcome of the SEC investigation? Unfortunately, the SEC’s processes are opaque and can take a long time. Shareholders are left to wonder: will Telix potentially face penalties or a cease-and-desist order if the SEC finds that disclosures were misleading? Or might this conclude as a non-event? Management’s credibility hangs in the balance. An explicit exoneration or closure of the inquiry would remove a dark cloud, whereas any enforcement action would be a serious blow. This open question may not be answered for many months, but it is critical – regulatory compliance and honesty in communication are paramount for a public company. Until resolved, this will weigh on Telix’s reputation.

– How will the class-action lawsuits impact Telix? While such lawsuits often take years and many are dismissed or settled without admission, they can still have implications. Will Telix’s management be deposed or internal documents come out that shed new light on 2025 events? Could potential damages or settlements meaningfully affect Telix’s finances (or will insurance cover most of it)? Shareholders will want to know if the company plans to fight the claims vigorously or seek a quick settlement to move forward. More broadly, is Telix making any changes to its governance or disclosure practices to address investor concerns? For example, adding independent board members, strengthening risk management, or improving how it guides the market on R&D progress. These would be constructive responses to shareholder unrest.

– Is Telix’s growth trajectory still intact? Telix issued very bullish revenue guidance for 2025 (up to A$1.23B) (^[8]) (^[8]), and the first half sales were on track (^[7]). But given the CRL and other headwinds, will the company still hit its growth targets? Illuccix demand appears strong, but one must ask: how much higher can Illuccix sales go before saturating the market? Also, how much of future growth was predicated on new product launches (like TLX250 or others) that may be delayed? Investors need to reassess Telix’s five-year growth plan in light of recent events. Is Telix still expecting to, say, double revenue by 2025–2026, or does that timeline shift out? Management’s next forecasts and commentary will be key to answering this.

– Are insiders aligned with long-term shareholder interests? The substantial insider sales in early 2025 raise an open question of alignment. While founders/insiders are entitled to take profit, the scale and timing were unsettling. Going forward, shareholders will be watching: Has insider selling continued? (Any further large divestments would be a negative signal.) Conversely, will insiders step up to buy shares at the now-depressed prices to demonstrate confidence? Actions such as insider buying or management opting to take more of their compensation in stock could help rebuild trust. This question boils down to whether management truly believes in the multiyear upside of Telix (if so, one would expect them to hold or add to their stakes now that the stock is lower).

– How will Telix manage its debt and capital needs? Telix’s current cash should fund near-term operations, but as mentioned, the A$650M convertible debt looms in 2029. If Telix’s strategy unfolds slower than expected, there might be a need for interim financing. Open questions include: Does Telix plan to raise additional capital (equity or debt) in the next year or two, perhaps to fund a major Phase III program or acquisition? Or do they expect internally generated cash to cover all investments going forward? Clarity on capital strategy is important. Shareholders should also inquire about contingency plans for the 2029 debt – for instance, would Telix consider a refinancing or incentivizing conversion earlier if the stock improves? Addressing these early could prevent a last-minute scramble down the line.

In summary, Telix is at a crossroads. The company’s core business (Illuccix) is performing well and has made Telix a rising star in biotech, but a series of missteps and external challenges have shaken confidence. Shareholders must stay engaged and demand transparency as the company works through these issues. The answers to the above questions will determine whether Telix can regain its stride or if deeper problems persist. Given the significant losses many shareholders have incurred, it’s reasonable for them to “act now” – whether by voicing concerns to management/board, seeking leadership changes, or participating in legal actions to protect their rights. The coming quarters will be crucial in seeing if Telix’s management can right the ship and deliver on its promising science, or if investors need to reconsider their commitment to this volatile story.

Sources

1. https://macrotrends.net/stocks/charts/TLX/Telix%20Pharmaceuticals%20Limited/stock-price-history
2. https://businesswire.com/news/home/20251117580138/en/Deadline-Approaching-Telix-Pharmaceuticals-Limited-TLX-Shareholders-Who-Lost-Money-Urged-to-Contact-Law-Offices-of-Howard-G.-Smith
3. https://dividendpedia.com/telix-pharmaceuticals/
4. https://telixpharma.com/news-views/telix-2023-full-year-results-inaugural-profit-achieved-strong-revenue-growth-underpins-investment-in-late-stage-pipeline/
5. https://reuters.com/business/healthcare-pharmaceuticals/australias-telix-pharma-raise-398-mln-debt-fund-cancer-therapy-2024-07-23/
6. https://telixpharma.com/news-views/telix-q3-2024-business-update-quarterly-revenue-exceeds-au200m/
7. https://aap.com.au/aapreleases/cision20250820ae56186/
8. https://ir.telixpharma.com/news-releases/news-release-details/telix-2024-full-year-results-record-financial-performance-and/
9. https://uk.finance.yahoo.com/quote/TLX.AX/
10. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-seeks-more-information-telix-pharmas-diagnostic-drug-kidney-cancer-2025-08-28/
11. https://sec.gov/Archives/edgar/data/1521036/000162828024006158/lnth-20231231.htm
12. https://stockhead.com.au/news/lunch-wrap-miners-muscle-the-asx-higher-but-telix-sinks-on-sec-subpoena/
13. https://prnewswire.com/news-releases/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-302618515.html
14. https://fool.com.au/2025/02/28/guess-which-asx-200-company-co-founders-just-sold-118-million-in-shares/

For informational purposes only; not investment advice.